NYU/Exiqon Team Finds New Blood-Based miRNA Markers for Melanoma Recurrence

Exiqon, which provided the array platform used for the miRNA discoveries, plans to work with the NYU team to validate the results with the eventual goal of creating a clinical prognostic test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.